IFNG and non-small cell lung carcinoma: Furthermore, a randomized controlled trial showed that favorable overall survival rates were observed in patients with high expression of T-effector-IFN-γ-associated genes, which was carried out in an NSCLC cohort pretreated by docetaxel or atezolizumab [36].